James P. Kelly serves as the Executive Vice President, Chief Financial Officer, and Treasurer at Novavax, Inc., a biotechnology company focused on developing vaccines for infectious diseases. With over two decades of experience in the finance and biotechnology sectors, Kelly has been instrumental in guiding Novavax through its growth and development phases. He joined the company in 2019 and has since played a crucial role in overseeing its financial strategies, including capital raising efforts and financial planning, which have been vital for advancing the company's research and development initiatives. Prior to his tenure at Novavax, Kelly held several high-profile positions that have shaped his expertise in financial management and strategic planning. He was the Chief Financial Officer at Seres Therapeutics, a microbiome therapeutics company, where he led the finance team through significant growth and multiple financings. Before Seres, Kelly served as the CFO at Inotek Pharmaceuticals and spent over a decade at Genzyme Corporation in various financial leadership roles. His extensive background in managing the financial aspects of biopharmaceutical companies has equipped him with the skills necessary to navigate the complex landscape of vaccine development and commercialization at Novavax. In his current role at Novavax, Kelly is responsible for ensuring the company's financial health and stability as it progresses through clinical trials and seeks regulatory approvals for its vaccine candidates. His strategic oversight has been crucial in securing funding and managing the company's resources efficiently, particularly during the global efforts to combat infectious diseases. Under his leadership, Novavax has been able to strengthen its financial position, which is essential for sustaining its mission to develop and deliver innovative vaccines to address critical health challenges worldwide.